SAGE Therapeutics (SAGE) Trading Up 6.8%

SAGE Therapeutics Inc (NASDAQ:SAGE)’s share price was up 6.8% during mid-day trading on Friday . The stock traded as high as $167.35 and last traded at $165.89. Approximately 728,768 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 607,235 shares. The stock had previously closed at $155.40.

Several equities analysts have issued reports on SAGE shares. J P Morgan Chase & Co dropped their price target on SAGE Therapeutics from $99.00 to $85.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 12th. Royal Bank of Canada dropped their price target on SAGE Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a research note on Monday, November 27th. Chardan Capital raised SAGE Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $140.00 in a research note on Friday, November 10th. Canaccord Genuity decreased their price objective on SAGE Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. Finally, Leerink Swann boosted their price objective on SAGE Therapeutics from $85.00 to $123.00 and gave the company a “positive” rating in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $171.21.

The stock has a market cap of $6,379.80, a price-to-earnings ratio of -24.15 and a beta of 3.03.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts expect that SAGE Therapeutics Inc will post -7.42 EPS for the current year.

In related news, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the sale, the insider now owns 152,759 shares in the company, valued at $24,354,367.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the sale, the chief executive officer now owns 211,473 shares of the company’s stock, valued at approximately $33,296,423.85. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in SAGE Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after purchasing an additional 724,494 shares during the period. BlackRock Inc. grew its stake in SAGE Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after purchasing an additional 168,424 shares during the period. New York State Common Retirement Fund grew its stake in SAGE Therapeutics by 258.0% in the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock valued at $9,318,000 after purchasing an additional 107,782 shares during the period. Farallon Capital Management LLC bought a new position in SAGE Therapeutics in the 2nd quarter valued at $7,964,000. Finally, State Street Corp grew its stake in SAGE Therapeutics by 7.7% in the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after purchasing an additional 87,097 shares during the period. Institutional investors and hedge funds own 95.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/12/24/sage-therapeutics-sage-trading-up-6-8.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit